NCT05550961|Recruiting
Loading search results
Sponsor study identifier
observational
1,200
1 country
1
Study Start
October 1, 2022
Actual (reported)Primary Completion
October 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
October 1, 2032
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
APOLLO 11 main aim is to build a strong Italian long-lasting lung cancer network (in around 48 Italian centres) on real world data and translational research by creating a decentralized long-term national database (settle locally in each centre) and a "virtual" multilevel biobank in each centre. Besides, APOLLO 11 will take advantage of the translational research joint effort with the credo "unity is strength".
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 1, 2032
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 19, 2022
Actual (reported)September 22, 2022
Actual (reported)October 1, 2022
Actual (reported)October 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
October 1, 2032
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Response Rate
Prediction of response to innovative therapies in NSCLC patients
About 8 weeks (first radiological evaluation)
Progression-Free Survival
Prediction of Progression-Free Survival in NSCLC patients treated with innovative therapies
From data of enrollment until the date of first documented progression or date of death from any cause, whichever come first, assessed up to 120 months
Overall Survival
Prediction of Overall Survival in NSCLC patients treated with innovative therapies
From data of enrollment until the date of death from any cause, assessed up to 120 months
About 1000 patients with NSCLC pre-treated with innovative therapy (e.g. immunotherapy, targeted therapy) will be included.
About 200 patients with NSCLC planned to start an innovative therapy (e.g. immunotherapy, targeted therapy) will be included.
Patients with NSCLC treated with innovative therapies in different Italian Centers will be enrolled in retrospective and prospective cohorts.
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Carlo Genova
IRCCS Ospedale Policlinico San Martino, Genova
Diego Signorelli
ASST Grande Ospedale Metropolitano Niguarda, Milano
Carminia Maria Della Corte
Azienda Ospedaliera Universitaria - Università degli Studi della Campania "Luigi Vanvitelli", Napoli
Giuseppe Viscardi
Ospedale Monaldi, Azienda Ospedaliera Dei Colli, Monaldi, Napoli
First Submitted
September 19, 2022
First Posted
September 22, 2022
Study Start
October 1, 2022
Actual (reported)Primary Completion
October 1, 2027
EstimatedRMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
Contact the study team to confirm eligibility.
Giulia Galli
Fondazione IRCCS Policlinico San Matteo di Pavia
Giulio Metro
Azienda Ospedaliera Santa Maria della Misercordia, Perugia
Raffaele Giusti
Azienda Ospedaliera Univesitaria S. Andrea, Roma
Marianna Macerelli
Azienda Ospedaliero-Universitaria Santa Maria Della Misericordia, Udine
Alessandro Inno
IRCCS Ospedale sacro Cuore Don Calabria NEGRAR
Rossana Berardi
A.O. universitaria Ospedali Riuniti di Ancona
Luca Toschi
Fondazione IRCCS Istituto clinico Humanitas
Michela Spreafico
Azienda Unità Sanitaria Locale della Romagna
Nicoletta Nanni
ASST Ospedale Cremona
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
October 1, 2032
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 23, 2023
Record last verified: 2023-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: